Company profile · Public records

Quagen

Free public records show Quagen in 1 of the markets we cover. It is not a key player in our research.

0Reports naming them
1Markets in public records
0Regions & countries
See reportsGrowth in full reports

Public data

Free public data on Quagen

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

US drug approvals

47 approvals with a product on the US market

Morphine Sulfate ANDA213892 · approved 7 Jul 2026
Glycopyrrolate ANDA216910 · approved 18 May 2026
Lidocaine Hydrochloride ANDA218676 · approved 20 Mar 2026
Potassium Chloride ANDA215716 · approved 22 Dec 2025
Aripiprazole ANDA215582 · approved 22 Oct 2025

Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.

See them on openFDA

Markets where public records show them

Markets we cover where free public records show Quagen: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Burn Ointment

Topics

The topics of the markets Quagen is in.

All topics

Wounds and burns

Search all reports for Quagen All companies